Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: An fMRI study

NeuroImage

Volumn 46, Issue 3, 2009, Pages 817-826

  Karageorgiou, John ^a   Dietrich, Mary S ^a,c   Charboneau, Evonne J ^a   Woodward, Neil D ^a   Blackford, Jennifer U ^a   Salomon, Ronald M ^a   Cowan, Ronald L ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Drug abuse; Movement; Neuroimaging; Serotonin; Toxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN;

ADULT; ARTICLE; BASAL GANGLION; BRAIN MAPPING; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABUSE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOBUS PALLIDUS; HUMAN; MALE; MOTOR CORTEX; MOTOR PERFORMANCE; NEUROTOXICITY; PRIORITY JOURNAL; PUTAMEN; SENSORY CORTEX; SEROTONINERGIC SYSTEM; TASK PERFORMANCE; THALAMOCORTICAL TRACT; THALAMUS;

ADOLESCENT; ADULT; BASAL GANGLIA; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MOVEMENT; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; TASK PERFORMANCE AND ANALYSIS; THALAMUS; YOUNG ADULT;

EID: 64949112741     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2009.02.029     Document Type: Article

References (62)

1. Alexander G.E., Crutcher M.D., and DeLong M.R. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog. Brain Res. 85 (1990) 119-146
2. Balogh B., Molnar E., Jakus R., Quate L., Olverman H.J., Kelly P.A., Kantor S., and Bagdy G. Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA. Psychopharmacology (Berl) 173 (2004) 296-309
3. Bankson M.G., and Cunningham K.A. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J. Pharmacol. Exp. Ther. 297 (2001) 846-852
4. Bondi M.W., Houston W.S., Eyler L.T., and Brown G.G. fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology 64 (2005) 501-508
5. Brett, M., Anton, J.L., Valabregue, R., Poline, J.B., 2002. Region of interest analysis using an SPM toolbox.
6. Buchert R., Thomasius R., Nebeling B., Petersen K., Obrocki J., Jenicke L., Wilke F., Wartberg L., Zapletalova P., and Clausen M. Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET. J. Nucl. Med. 44 (2003) 375-384
7. Buchert R., Thomasius R., Wilke F., Petersen K., Nebeling B., Obrocki J., Schulze O., Schmidt U., and Clausen M. A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. Am. J. Psychiatry 161 (2004) 1181-1189
8. Carter C.S., Heckers S., Nichols T., Pine D.S., and Strother S. Optimizing the design and analysis of clinical functional magnetic resonance imaging research studies. Biol. Psychiatry 64 (2008) 842-849
9. Cowan R.L. Neuroimaging research in human MDMA users: a review. Psychopharmacology (Berl) 189 (2007) 539-556
10. Cowan R.L., Haga E., deB F.B., Dietrich M.S., Vimal R.L., Lukas S.E., and Renshaw P.F. MDMA use is associated with increased spatial BOLD fMRI visual cortex activation in human MDMA users. Pharmacol. Biochem. Behav. 84 (2006) 219-228
11. Cowan R.L., Bolo N.R., Dietrich M., Haga E., Lukas S.E., and Renshaw P.F. Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users. Psychiatry Res. 155 (2007) 179-188
12. Cowan R.L., Bolo N.R., Dietrich M., Haga E., Lukas S.E., and Renshaw P.F. Occipital cortical proton MRS at 4 Tesla in human moderate MDMA polydrug users. Psychiatry Res. 155 (2007) 179-188
13. Cowan R.L., Roberts D.M., and Joers J.M. Neuroimaging in human MDMA (Ecstasy) users. Ann. N.Y. Acad. Sci. 1139 (2008) 291-298
14. Daumann J., Fimm B., Willmes K., Thron A., and Gouzoulis-Mayfrank E. Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study. Brain Res.Cogn Brain Res. 16 (2003) 479-487
15. Daumann J., Schnitker R., Weidemann J., Schnell K., Thron A., and Gouzoulis-Mayfrank E. Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users. Neuroreport 14 (2003) 1983-1987
16. Daumann J., Fischermann T., Pilatus U., Thron A., Moeller-Hartmann W., and Gouzoulis-Mayfrank E. Proton magnetic resonance spectroscopy in ecstasy (MDMA) users. Neurosci. Lett. 362 (2004) 113-116
17. Daumann J., Hensen G., Thimm B., Rezk M., Till B., and Gouzoulis-Mayfrank E. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology (Berl) 173 (2004) 398-404
18. Daumann J., Fischermann T., Heekeren K., Henke K., Thron A., and Gouzoulis-Mayfrank E. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology (Berl) 180 (2005) 607-611
19. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C., Olabarriaga S.D., den Heeten G.J., and van den B.W. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131 (2008) 2936-2945
20. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C., Olabarriaga S.D., Ramsey N.F., Heeten G.J., and van den B.W. Neurotoxic effects of ecstasy on the thalamus. Br. J. Psychiatry 193 (2008) 289-296
21. DeVito J.L., Anderson M.E., and Walsh K.E. A horseradish peroxidase study of afferent connections of the globus pallidus in Macaca mulatta. Exp. Brain Res. 38 (1980) 65-73
22. Fals-Stewart W., O'Farrell T.J., Freitas T.T., McFarlin S.K., and Rutigliano P. The timeline followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J. Consult. Clin. Psychol. 68 (2000) 134-144
23. Fink K.B., and Gothert M. 5-HT receptor regulation of neurotransmitter release. Pharmacol. Rev. 59 (2007) 360-417
24. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version (1997), American Psychiatric Press, Washington, D.C
25. Fransson P., Kruger G., Merboldt K.D., and Frahm J. Temporal and spatial MRI responses to subsecond visual activation. Magn Reson.Imaging 17 (1999) 1-7
26. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
27. Gyongyosi N., Balogh B., Kirilly E., Kitka T., Kantor S., and Bagdy G. MDMA treatment 6 months earlier attenuates the effects of CP-94,253, a 5-HT(1B) receptor agonist, on motor control but not sleep inhibition. Brain Res. 1231 (2008) 34-46
28. Herrero M.T., Barcia C., and Navarro J.M. Functional anatomy of thalamus and basal ganglia. Childs Nervous System 18 (2002) 386-404
29. Holland B.S., and Copenhaver M.D. An improved sequentially rejective Bonferroni test procedure. Biometrics 43 (1987) 417-424
30. Holsapple J.W., Preston J.B., and Strick P.L. The origin of thalamic inputs to the "hand" representation in the primary motor cortex. J. Neurosci. 9 (1991) 2644-2654
31. Hornung J.P. The human raphe nuclei and the serotonergic system. J. Chem. Neuroanat. 26 (2003) 331-343
32. Jacobs B.L., and Fornal C.A. Serotonin and motor activity. Curr. Opin. Neurobiol. 7 (1997) 820-825
33. Jacobsen L.K., Mencl W.E., Pugh K.R., Skudlarski P., and Krystal J.H. Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 173 (2004) 383-390
34. Jager G., de Win M.M., Vervaeke H.K., Schilt T., Kahn R.S., van den B.W., van Ree J.M., and Ramsey N.F. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Psychopharmacology (Berl) 193 (2007) 403-414
35. Jager G., de Win M.M., Vervaeke H.K., Schilt T., Kahn R.S., van den B.W., van Ree J.M., and Ramsey N.F. Incidental use of ecstasy: no evidence for harmful effects on cognitive brain function in a prospective fMRI study. Psychopharmacology (Berl) 193 (2007) 403-414
36. Jager G., de Win M.M., van D.T.I., Schilt T., Kahn R.S., van den B.W., van Ree J.M., and Ramsey N.F. Assessment of cognitive brain function in ecstasy users and contributions of other drugs of abuse: results from an FMRI study. Neuropsychopharmacology 33 (2008) 247-258
37. Jager G., de Win M.M., van D.T.I., Schilt T., Kahn R.S., van den B.W., van Ree J.M., and Ramsey N.F. Assessment of cognitive brain function in ecstasy users and contributions of other drugs of abuse: results from an FMRI study. Neuropsychopharmacology 33 (2008) 247-258
38. Johnston, L.D., O'Malley, P.M., Bachman, J.G., Schulenberg, J.E., 2007. Monitoring the future survey, national results on adolescent drug use: overview of key findings. The University of Michigan Institute for Social Research.
39. Lavoie B., and Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J. Comp. Neurol. 299 (1990) 1-16
40. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., and Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352 (1998) 1433-1437
41. McCann U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W.B., Ravert H.T., Dannals R.F., and Ricaurte G.A. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30 (2005) 1741-1750
42. McCann, U.D., Szabo, Z., Vranesic, M., Palermo, M., Mathews, W.B., Ravert, H.T., Dannals, R.F., Ricaurte, G.A., 2008. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl).
43. McQuade R., and Sharp T. Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J. Neurochem. 69 (1997) 791-796
44. Moeller F.G., Steinberg J.L., Dougherty D.M., Narayana P.A., Kramer L.A., and Renshaw P.F. Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl) 177 (2004) 185-194
45. Moeller F.G., Steinberg J.L., Lane S.D., Buzby M., Swann A.C., Hasan K.M., Kramer L.A., and Narayana P.A. Diffusion tensor imaging in MDMA users and controls: association with decision making. Am. J. Drug Alcohol Abuse 33 (2007) 777-789
46. Mohamed M.A., Yousem D.M., Tekes A., Browner N., and Calhoun V.D. Correlation between the amplitude of cortical activation and reaction time: a functional MRI study. AJR Am. J. Roentgenol. 183 (2004) 759-765
47. NIH, 2008a. NCT00353938: Study of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in people with posttraumatic stress disorder.
48. NIH, 2008b. NCT00402298: Randomized placebo-controlled study of MDMA-assisted psychotherapy in people with PTSD - Israel.
49. Obrocki J., Schmoldt A., Buchert R., Andresen B., Petersen K., and Thomasius R. Specific neurotoxicity of chronic use of ecstasy. Toxicol. Lett. 127 (2002) 285-297
50. Obrocki J., Schmoldt A., Buchert R., Andresen B., Petersen K., and Thomasius R. Specific neurotoxicity of chronic use of ecstasy. Toxicol. Lett. 127 (2002) 285-297
51. Parrott A.C. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 173 (2004) 234-241
52. Poldrack R.A. Region of interest analysis for fMRI. Soc. Cogn. Affect. Neurosci. 2 (2007) 67-70
53. Reneman L., Habraken J.B., Majoie C.B., Booij J., and den Heeten G.J. MDMA ("Ecstasy") and its association with cerebrovascular accidents: preliminary findings. AJNR Am. J. Neuroradiol. 21 (2000) 1001-1007
54. Sidak Z. Rectangular confidence regions for the means of multivariate normal distributions. J. Am. Stat. Assoc. 62 (1967) 626-633
55. Substance Abuse and Mental Health Services Administration, 2008. The national survey on drug use and health (NSDUH). Substance Abuse and Mental Health Services Administration, Office of Applied Studies.
56. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., and Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15 (2002) 273-289
57. United Nations. World drug report (2008), United Nations, Office on Drugs and Crime
58. Valdes I.H., Steinberg J.L., Narayana P.A., Kramer L.A., Dougherty D.M., Swann A.C., Barratt E.S., and Moeller F.G. Impulsivity and BOLD fMRI activation in MDMA users and healthy control subjects. Psychiatry Res. 147 (2006) 239-242
59. Vannini P., Almkvist O., Dierks T., Lehmann C., and Whalund L.O. Reduced neuronal efficacy in progressive mild cognitive impairment: a prospective fMRI study on visuospatial processing. Psychiatry Research. Neuroimaging 156 (2007) 43-57
60. Wilson M.A., and Molliver M.E. The organization of serotonergic projections to cerebral cortex in primates: regional distribution of axon terminals. Neuroscience 44 (1991) 537-553
61. Wilson M.A., Ricaurte G.A., and Molliver M.E. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 28 (1989) 121-137
62. Wish E.D., Fitzelle D.B., O'Grady K.E., Hsu M.H., and Arria A.M. Evidence for significant polydrug use among ecstasy-using college students. J. Am. Coll. Health 55 (2006) 99-104